Rituximab in treatment of idiopathic glomerulopathy
Affiliations
Affiliations
- Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait. hosam20@hotmail.com
Abstract
The aim of our study was to assess the role of rituximab (Mabthera) in the treatment of patients with corticosteroid-resistant and calcineurin-inhibitors ± cellcept refractory idiopathic nephrotic syndrome (INS). A total of 83 patients who had required the previous treatment for a minimum of two years were included in the study. Our protocol included the use of rituximab in four-weekly slow infusions. Five patients were excluded as they could not tolerate rituximab infusion for allergic reaction. As expected, none of the patients had a decline in the total circulating lymphocyte counts yet all had achieved decline of their initially normal CD20 to < 0.5% one month after infusion. The decline persisted for eight to ten months later. In the minimal change disease (MCD) group, 31 of the 32 patients had complete remission (CR) and were off any immunosuppressive therapy and one of the previous non-responders (NR) did not respond. Excluding two patients who had required retreatment, the others remained in CR (17 up to 28 months and six up to 36 months). Treatment with rituximab resulted in amelioration of NS in 17 of the 18 patients with focal segmental glomerulosclerosis (FSGS), while only one patient remained NR. Although renal function remained stable, proteinuria reappeared by eight to 12 months. Retreatment with rituximab resulted in a similar response with stable kidney function. In the 28 patients with membranous glomerulopathy (MG), 24 had achieved CR. Two patients failed to respond and two had partial remission. By 12 months, all patients relapsed. The response was within one month following treatment in patient with MCD, but was gradual within three months in FSGS and MG. Relapsers in all groups responded in a similar pattern to repeat dosing with the drug subsequently. Our prospective study represents an adequate number of patients with biopsy-proven subgroups of INS in both children and adults with long-term follow-up of treatment with rituximab. The drug is effective and safe for treatment of patients refractory to the conventional agents.
Similar articles
Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome.
Basu B, Mahapatra TK, Mondal N.Pediatrics. 2015 Jul;136(1):e132-9. doi: 10.1542/peds.2015-0486.PMID: 26101364
Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM.Kidney Int. 2013 Nov;84(5):1025-33. doi: 10.1038/ki.2013.211. Epub 2013 Jun 5.PMID: 23739238 Free PMC article.
Kisner T, Burst V, Teschner S, Benzing T, Kurschat CE.Nephron Clin Pract. 2012;120(2):c79-85. doi: 10.1159/000335142. Epub 2012 Jan 26.PMID: 22286071 Review.
El-Reshaid K, El-Reshaid W, Madda J.Ren Fail. 2005;27(5):523-30. doi: 10.1080/08860220500198623.PMID: 16152989 Clinical Trial.
Treatment of FSGS in Children.
Sethna CB, Gipson DS.Adv Chronic Kidney Dis. 2014 Mar;21(2):194-9. doi: 10.1053/j.ackd.2014.01.010.PMID: 24602468 Review.
Cited by
Rituximab Dosing in Glomerular Diseases: A Scoping Review.
Alzayer H, Sebastian KK, O'Shaughnessy MM.Can J Kidney Health Dis. 2022 Oct 18;9:20543581221129959. doi: 10.1177/20543581221129959. eCollection 2022.PMID: 36275037 Free PMC article. Review.
Ren H, Lin L, Shen P, Li X, Xie J, Pan X, Zhang W, Chen N.Oncotarget. 2017 Oct 15;8(55):93438-93443. doi: 10.18632/oncotarget.21833. eCollection 2017 Nov 7.PMID: 29212162 Free PMC article.
Podocytes from the diagnostic and therapeutic point of view.
Müller-Deile J, Schiffer M.Pflugers Arch. 2017 Aug;469(7-8):1007-1015. doi: 10.1007/s00424-017-1993-z. Epub 2017 May 16.PMID: 28508947 Review.
Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.
Niu XL, Hao S, Wang P, Zhang W, Guo GM, Wu Y, Kuang XY, Zhu GH, Huang WY.Biomed Rep. 2016 Aug;5(2):237-242. doi: 10.3892/br.2016.711. Epub 2016 Jun 30.PMID: 27446549 Free PMC article.